FDA Finalizes Controlled Correspondence Guidance for Generic Drugmakers

The FDA has issued a final guidance on the process generic drug manufacturers can use to correspond with the agency on generic drug development, the agency’s process for responding and for manufacturers to clarify ambiguities in what the FDA refers to as “controlled correspondence.”
Source: Drug Industry Daily